Complex Genomic Reports and Future Considerations

Dr. Wistuba addresses the complexity of NGS reports that may include multiple abnormalities beyond ROS1 fusions. Although ROS1-positive patients typically do not have concurrent EGFR or ALK alterations, reports may show additional findings such as KRAS, TP53, RB loss, or AKT abnormalities. For treatment purposes, ROS1 status represents the primary consideration, with other abnormalities potentially relevant for future resistance mechanism understanding but not influencing initial treatment decisions.

Dr. Leal discusses the potential for sustained disease control with modern ROS1 inhibitors, noting extremely prolonged responses lasting more than 5 years in multiple patients. As longer-term follow-up data becomes available, important considerations include the possibility of turning this into a chronic disease paradigm, understanding durability patterns, CNS response durability, identification of late toxicities with longer follow-up, overall survival outcomes, and quality of life implications.

Real-world data becomes particularly important for comprehensive understanding of patient experiences. Dr. Leal emphasizes that patients with ROS1-positive disease can demonstrate very high PD-L1 expression, which represents a potential diagnostic pitfall. Unlike other cancers where high PD-L1 expression suggests immunotherapy efficacy, ROS1-positive patients should not receive PD-L1 inhibitor monotherapy as the primary treatment approach, as targeted therapy represents the superior option.

Dr. Wistuba explains that PD-L1 overexpression in ROS1-positive disease results from constitutive activation by ROS1 activation rather than microenvironmental factors, leading to high PD-L1 expression without significant tumor-infiltrating lymphocytes. This biological understanding reinforces why immunotherapy does not provide optimal outcomes for these patients compared to targeted approaches.

Dr. Rodriguez emphasizes patient education and counseling about treatment paradigms, noting that many patients receive diagnoses during routine medical evaluations such as coronary CT scans. Determining whether patients truly need immediate chemotherapy versus addressing anxiety and fear becomes crucial, as one cycle of chemotherapy provides minimal disease impact for stable patients who can safely wait for comprehensive testing results.